摘要
目的探讨口服砷剂对急性早幼粒细胞白血病维持治疗的临床治疗效果。方法选取我院近6年经ATRA和化疗联合诱导分化达完全缓解（CR）,再进行序贯化疗巩固治疗4个疗程后,处于分子水平缓解的75名患者为研究对象,采用随机数表法随机分为砷剂组（n=40）与非砷剂组（n=35）两组。非砷剂组采用小剂量化疗（MTX＋6-MP）联合全反式维甲酸（ATRA）方案,砷剂组在上述基础上予以口服砷剂（复方黄黛片）24个月进行治疗,长期观察后对比两组治疗方案的临床疗效及不良反应。结果在6个月-5年的随访过程中砷剂组预计治疗后5年内无复发生存率及总生存率分别为（83.3±5.3）%和（87.3±5.4）%,均高于非砷剂组的（62.6±6.6）%和（77.4±6.8）%,组间对比差异有统计学意义（P〈0.05）;两组不良反应发生率差异不具有统计学意义（P〉0.05）。结论加服砷剂对急性早幼粒细胞白血病患者中远期治疗效果的提升具有积极意义,可延长生存时间,减少病症复发风险,提高患者的长期无复发生存率。
Objective To investigate the clinical effect of oral arsenicals on maintenance treatment of acute promyelocytic leukemia.Methods Seventy-five patients with molecular remission who met research conditions were selected and randomly divided into arsenicals group（n = 40） and non arsenicals group（n = 35）. The non arsenicals group was given small doses of chemotherapy（MTX ＋ 6-MP）combined with all-trans retinoic acid（ATRA）, and the arsenicals group was given arsenicals by oral administration for 24 months on the basis of program of non arsenicals group. The clinical efficacy and adverse reactions were observed and compared between two groups.Results The expected relapse-free survival rate and overall survival rate during 5 years of arsenicals group were（83.3 ± 5.3） % and（87.3 ±5.4） % respectively, significantly higher than（62.6 ± 6.6） % and（77.4 ± 6.8） % of non arsenicals group respectively（P〈0.05）. The difference of incidence of adverse reactions between two groups was not statistically significant（P〉0.05）. Conclusions Arsenicals by oral administration have positively significance in improving middle and long term treatment effect of patients with acute promyelocytic leukemia.It can effectively prolong the survival time, reduce the risk of symptoms recurrence, and improve patients＇ long-term relapse-free survival rate.
出处
《临床医学工程》
2015年第1期33-34,共2页
Clinical Medicine & Engineering
关键词
砷剂
急性早幼粒细胞白血病
维持治疗
预后质量
Arsenicals
Acute promyelocytic leukemia（APL）
Maintenance treatment
Prognosis quality
